Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

Insurance industry boasts 11% reduction in prior authorizations since 2025 reform rollout
That equates to eliminating 6.5 million prior authorization barriers. The results come from a survey of major health plans conducted by AHIP and the Blue Cross Blue Shield Association.
Long-term cardiac amyloidosis survival benefits seen in extension acoramidis trial
Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.
Johnson & Johnson launches faster PFA system in Europe
The new version of the PFA system is five times faster than the current catheter to improve workflow.
FDA clears way for IDE pivotal trial of the Topaz tricuspid valve replacement system
The TRiCares Topaz uses a unique two-stent frame valve prosthesis for better sealing and flexibility.
Interventional radiologist 1st in world to deliver newly approved cancer treatment
The completion of the first treatment represents a "significant milestone" for patients with liver cancer, the IR who led the procedure says.

Insurance industry boasts 11% reduction in prior authorizations since 2025 reform rollout

That equates to eliminating 6.5 million prior authorization barriers. The results come from a survey of major health plans conducted by AHIP and the Blue Cross Blue Shield Association.

Prem Soman, MD, director of the Cardiac Amyloidosis Center and nuclear cardiology, and associate chief of cardiology at the University of Pittsburgh Medical Center Heart and Vascular Institute presented the late-breaking results from the long-term survival benefits and disease stabilization with the drug acoramidis in patients with transthyretin amyloid cardiomyopathy at ACC 2026.

Long-term cardiac amyloidosis survival benefits seen in extension acoramidis trial

Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.

Johnson & Johnson announced the launch of its new Varipulse Pro pulsed field ablation (PFA) system in Europe following CE mark approval. It is five times faster at ablation delivery at a cooler temperature than the previous version.

Johnson & Johnson launches faster PFA system in Europe

The new version of the PFA system is five times faster than the current catheter to improve workflow.

The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to conduct a pivotal clinical trial for TRiCares Topaz transcatheter tricuspid valve replacement (TTVR) system in the U.S. The TTVR system uses two stent frames, one for the valve and one to engage the annulus with a membrane shirt between them to enable flexing of the outer ring to better seal against regurgitation.expansing stents

FDA clears way for IDE pivotal trial of the Topaz tricuspid valve replacement system

The TRiCares Topaz uses a unique two-stent frame valve prosthesis for better sealing and flexibility.

Interventional radiologist 1st in world to deliver newly approved cancer treatment

The completion of the first treatment represents a "significant milestone" for patients with liver cancer, the IR who led the procedure says.

Therapy-related acute myeloid leukemia is an aggressive form of blood cancer and bone marrow that occurs in the years following radiation and chemotherapy.

To unpack the large number of lat-breaking trials at the American College of Cardiology 2026 meeting, Cardiovascular Business spoke in the above video interview with Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, director of the Mount Sinai Fuster Heart Hospital, who highlighted several studies he felt had the most scientific impact. This included a mix of drug, device and strategy trials pointing to advances in cardiology. #ACC #ACC26

Deepak Bhatt discusses some of the most impactful trials at ACC 2026

Bhatt describes a mix of drug, device and strategy trials pointing to advances in cardiovascular science.

Screening and treatment for chronic kidney disease in heart disease patients needs to be expanded

The risk associated with under-recognized CKD emerged early, highlighting the need for screening soon after a CAD diagnosis so that cardio-renal protective drugs can be started much earlier.